
Solid Biosciences (SLDB) Stock Forecast & Price Target
Solid Biosciences (SLDB) Analyst Ratings
Bulls say
Solid Biosciences Inc is making significant strides in addressing Duchenne muscular dystrophy (DMD) through its innovative pipeline, with projections indicating that SGT-003 could generate risk-adjusted revenues of $1 billion by 2033, up from $90 million in 2028. Promising early clinical data demonstrates improvements in cardiac function and key biomarkers indicative of enhanced muscle integrity, suggesting strong underlying efficacy for the company's gene therapy approach. Additionally, the company is adapting its evaluation metrics to better capture functional benefits over more extended analysis periods, reinforcing the potential for expanded market reach and validation of its therapeutic technologies.
Bears say
Solid Biosciences Inc faces significant risks that contribute to a negative outlook for its stock. The primary concern stems from the uncertainty surrounding regulatory approval for its lead gene therapy candidate, SGT-003, with potential failure to secure approval or delays leading to downward revisions in risk-adjusted projections and price targets. Additionally, the company may struggle with manufacturing capacity limitations, which could materially constrain sales of SGT-003, exacerbating financial instability amid broader industry challenges in gene therapy development.
This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares